Media stories about Cellect Biotechnology (NASDAQ:APOP) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellect Biotechnology earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 43.6370387667751 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Separately, ValuEngine raised shares of Cellect Biotechnology from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st.
Shares of Cellect Biotechnology (NASDAQ:APOP) opened at 6.638 on Thursday. The company has a 50-day moving average of $7.84 and a 200 day moving average of $7.42. Cellect Biotechnology has a one year low of $2.30 and a one year high of $13.50. The stock’s market cap is $35.71 million.
WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/08/10/cellect-biotechnology-nasdaqapop-given-daily-coverage-optimism-score-of-0-17.html.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.